Novo Nordisk Enters a New License Agreement for the Enterprise Execution Software Howwe®
Novo Nordisk, a global healthcare company committed to preventing and treating diabetes, obesity, and other serious chronic diseases, has entered into a new license agreement with Howwe Technologies, an enterprise execution software provider. The partnership, which began in 2017, generated a return on investment of 20 times for Novo Nordisk already in 2018. The license agreement will now be extended until 2025.Through this partnership, Novo Nordisk will be able to leverage Howwe Technologies' expertise in enterprise execution to further accelerate its work towards achieving strategic goals,